drugset / Trial / NCT05749081

Helicobacter Pylori and Lacidophilin Tablets in Combination With Vonorazan Dual Therapy

NCT05749081

RandomizedParallel-groupDouble-blindTreatment

Summary

Our previous study included 119 Helicobacter pylori(H. pylori)-infected Chinese patients without previous eradication history who were randomized to low-or high-dose amoxicillin-vonoprazan regimens consisting of amoxicillin 1 gram either b.i.d. or t.i.d plus vonoprazan 20 mg b.i.d for 7 or 10 days. Neither 7-or 10-day VA dual therapy with either b.i.d. or t.i.d. amoxicillin achieved satisfied efficacy (i.e., \<90%) when given as first-line treatment for H. pylori infection. Lacidophilin tablets have been reported to increase the eradication rate of H. pylori while reducing the incidence of adverse effects.This study evaluated the efficacy and safety of lacidophilin tablets in combination with amoxicillin-vonoprazan dual therapy for 10 days as first-line treatment for H. pylori in China.

Timeline

Start
2023-05-13
Primary completion
2024-07
Completion
2024-07

Drugs

EvaluationDrugModalityDoseRoute
Subject lacidophilin Unknown 2400 mg
Background Amoxicillin Other / unclassified 1000 mg
Background Vonoprazan Other / unclassified 20 mg